Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $16.00

SAB Biotherapeutics (NASDAQ:SABS) had its target price upped by equities researchers at Chardan Capital from $14.00 to $16.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 337.16% from the company’s current price.

SABS has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of SAB Biotherapeutics in a report on Monday. Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Leerink Partners boosted their target price on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.88.

SAB Biotherapeutics Price Performance

SABS opened at $3.66 on Wednesday. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 52-week low of $1.65 and a 52-week high of $6.60. The company has a 50 day moving average of $3.69 and a two-hundred day moving average of $3.85. The company has a market cap of $279.84 million, a P/E ratio of -1.73 and a beta of 0.54.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). On average, analysts expect that SAB Biotherapeutics will post -1.19 earnings per share for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SABS. Commodore Capital LP purchased a new stake in SAB Biotherapeutics during the third quarter valued at about $8,847,000. Simplify Asset Management Inc. purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at about $779,000. Propel Bio Management LLC purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at about $2,442,000. Spruce Street Capital LP purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at about $8,222,000. Finally, Jefferies Financial Group Inc. purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at about $2,170,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.